Last reviewed · How we verify
NCT06294678
Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies
Phase 3 trial testing Time of stem cell infusion in Acute Graft-versus-host Disease in 198 participants. Participants enrolled and being followed up; not accepting new ones.
30 September 2025
Quick facts
| Lead sponsor | Anhui Provincial Hospital |
|---|---|
| Phase | Phase 3 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 198 |
| Start date | 1 March 2024 |
| Primary completion | 30 September 2025 |
| Estimated completion | 31 August 2026 |
| Sites | 6 locations across China |
Drugs / interventions tested
- Time of stem cell infusion
Conditions studied
- Acute Graft-versus-host Disease — all drugs for Acute Graft-versus-host Disease →
Sponsor
Anhui Provincial Hospital
Who can join
Adults 12 to 60, any sex, with Acute Graft-versus-host Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To observe the effect of stem cell infusion on the development of acute graft-versus-host disease (aGVHD) in patients with malignant hematologic diseases after allogeneic peripheral blood hematopoietic stem cell transplantation (allo-PBSCT)
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Chrono-immunotherapy's current and future optimization strategies: immunotherapy timing in line with the circadian rhythm brings longer survival benefits.
Liu D, Li Z, Cui H, Zhang H, et al · · 2026 · PMID 41777887 · DOI 10.3389/fimmu.2026.1777437 -
Influence of time-of-day of graft infusion on allogeneic hematopoietic stem cell transplantation outcomes: a validation cohort study.
Bernardi C, Pradier A, Masouridi-Levrat S, Morin S, et al · · 2025 · PMID 41448834 · DOI 10.1136/jitc-2025-013372
Verify or expand the search:
- PubMed search for NCT06294678
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Time of stem cell infusion
Trials testing the same drug.
- NCT06294691 — Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases · Phase 3 · recruiting
Other recruiting trials for Acute Graft-versus-host Disease
Currently open trials in the same condition.
- NCT06936566 — MAGIC Ruxolitinib for aGVHD · Phase 2 · recruiting
- NCT06294691 — Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases · Phase 3 · recruiting
- NCT02611180 — Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease · active not recruiting
Other Anhui Provincial Hospital trials
Trials by the same sponsor.
- NCT07523464 — Centrally Confined 8Gy/1f to Tumor Core Followed by Concurrent Chemoradiotherapy for Unresectable Stage III NSCLC · Phase 1 · not yet recruiting
- NCT07481656 — Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT) · Phase 4 · not yet recruiting
- NCT07462676 — Simultaneous Vs Staged VPS and CP :A Multi-cnter RCT. · NA · not yet recruiting
- NCT07211048 — Anti CD19 Gene Therapy for B-cell Lymphoma · NA · recruiting
- NCT07279844 — An Open-label, Observational, Long-term Follow-up Study Evaluating the Safety and Efficacy of RGL-193 Putamen Injection · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06294678 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Anhui Provincial Hospital
- Last refreshed: 31 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06294678.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing